Arrowhead Research VP of Intellectual Property to Speak at NanoBusiness 2006
Beyond serving as vice president, intellectual property for Arrowhead Research Corporation, Miller is founder of NanoPolaris, Inc., a wholly owned subsidiary of Arrowhead Research Corporation, which offers a customized nanotube patent portfolio licensing program.
“The Handbook of Nanotechnology Business, Policy, and Intellectual Property Law”
Miller is also managing editor of Nanotechnology Law & Business, a peer-reviewed, quarterly journal. He has published various articles on nanotechnology legal and policy issues and co-authored "The Handbook of Nanotechnology Business, Policy, and Intellectual Property Law" (John Wiley, 2004). He is a member of the California Bar and federal courts in the Northern District of California.
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) is a diversified nanotechnology company structured to commercialize products expected to have revolutionary impacts on a variety of industries, including materials, electronics, life sciences, and energy.
There are three strategic components to Arrowhead's business model:
-- Outsourced R&D Program: Arrowhead identifies patented or patent-pending technologies at universities or government labs and funds additional development of those technologies in exchange for exclusive rights to commercialize the resulting prototypes. Leveraging the resources and infrastructure of these institutions provides Arrowhead with a cost-effective development pipeline. Currently, Arrowhead is supporting efforts in drug discovery tools, stem cell technology, and nanoelectronics at the California Institute of Technology, Stanford University, and Duke University, respectively.
-- Commercialization Program: After prototypes have been sufficiently developed in the laboratories, Arrowhead forms or acquires majority-owned subsidiaries to commercialize the technology and provides the subsidiaries with strategic, managerial, and operational support. By doing so, each research team is able to maintain focus on its specific technology and each management team can focus on specific markets, increasing the likelihood of successful technological development and commercialization. At present, Arrowhead owns majority interest in subsidiaries commercializing diverse technologies, including anti-cancer drugs, RNAi therapeutics, compound semiconductor materials, and nanotube technology.
-- The Patent Toolbox: Arrowhead has acquired or exclusively licensed patents and patent applications covering a broad range of nanotechnology. The Company actively adds to its intellectual property portfolio.
About NanoPolaris, Inc.
NanoPolaris is a wholly owned subsidiary of Arrowhead Research Corporation. With exclusively licensed commercial rights to nanotube technology developed at some of the world's most respected research universities, the NanoPolaris IP portfolio includes patents and patent applications claiming nanotube compositions of matter and general manufacturing techniques such as chemical vapor deposition synthesis, plasma chemical vapor deposition synthesis, purification, solubilization, separation of certain types of tubes, coatings, functionalization, and manipulation. NanoPolaris is developing a customized portfolio license program for customers in different industries who will utilize nanotube technology with their products.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies; the future success of our scientific studies; our ability to successfully develop products; rapid technological change in our markets; changes in demand for our future products; legislative, regulatory, and competitive developments; and general economic conditions. Our Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations, and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.